Top Medical News
Elvira Manzano, 6 days ago
There is insufficient evidence to assess the harms and benefits of using pelvic examinations to screen for gynaecologic conditions in asymptomatic nonpregnant adult women, according to a recommendation statement issued by the US Preventive Services Task Force (USPSTF).
Jackey Suen, 9 days ago

Long-term use of oral nucleos(t)ide analogues (NAs) in patients with chronic hepatitis B (CHB) infection does not increase cancer risk, a recent large population-based study has shown.

9 days ago
Plasma concentrations of colistin do not appear to be associated with clinical cure and 30-day mortality in the treatment of infections caused by extremely drug-resistant (XDR) Pseudomonas aeruginosa, according to a Spanish prospective observational cohort study.
10 days ago
The novel oxazolidinone tedizolid appears to be clinically superior to vancomycin and comparable with other monotherapy drugs in treating serious skin infections caused by methicillin-resistant Staphylococcus aureus (MRSA), according to a systematic review and network meta-analysis.
10 days ago
Plasma presepsin appears to be an effective diagnostic marker for febrile neutropaenia (FN) in patients on massive chemotherapy, according to a Japanese study.
10 days ago
Probiotics have a long history of use in humans. Defined as "live organisms that confer a health benefit on the host when administered in adequate amounts", the spectrum of use of probiotics in humans ranges from foods and dietary supplements to pharmaceutical/nutraceutical products to affect general health and disease. While the genera Lactobacillus and Bifidobacterium are the two most common probiotics associated with consumer products, there exist other organisms (eg, the yeast Saccharomyces cerevisiae, some non-pathogenic strains of Escherichia coli and Bacillus species) that are used as probiotics.1–3 One of them is the probiotic strain B. clausii that has been found to be effective for the treatment of diarrhoea and antibiotic-associated gastrointestinal side effects.4–6
Roshini Claire Anthony, 11 days ago

Educating patients on the outcomes of inappropriate antibiotic use has a limited effect in reducing their likelihood of receiving an antibiotic prescription, a local study found. 

Special Reports
01 Mar 2017
At the recent Asia Pacific Alliance for the Control of Influenza (APACI) workshop in Kuala Lumpur, MIMS Doctor had the privilege of having an exclusive interview with eminent paediatric infectious disease specialist, Associate Professor Tawee Chotpitayasunondh. This article captures the highlights from our conversation with him.
Stephen Padilla, 06 Dec 2016
Dengvaxia, a recombinant, live-attenuated dengue vaccine, has the potential to bring down the number of hospitalizations by 13 to 25 percent and be cost-effective in areas of moderate-to-high dengue endemicity, according to a model comparison study.
02 Dec 2016
The Asia Pacific Alliance for the Control of Influenza (APACI) recently organized an influenza workshop in Kuala Lumpur. The workshop saw eminent speakers from seven countries presenting on topics concerning the impact of influenza, vaccination of various populations, current and upcoming treatments for influenza, policy considerations and approaches for pandemic preparedness. Read about highlights from the workshop in this newsletter. 
23 Nov 2016
At the recent Infectious Disease Symposium held on the 5th of August 2016, at Le Meridien Kuala Lumpur, two speakers spoke on the role of macrolides in the management of respiratory tract infections, as well as the importance of antibiotic stewardship in combating microbial resistance.
Dr. Joslyn Ngu, 19 Aug 2016

The rise of anti-malarial resistant Plasmodium falciparum in areas where malaria is endemic, such as Southeast Asia, calls for the safe and right use of current antimalarials.

30 Jul 2016
Antimicrobial resistance is an increasingly serious threat to global public health. To address this, Associate Professor de Castro recently sat down with MIMS Doctor to give her views on the judicious use of antimicrobial agents.
Roshini Claire Anthony, 05 Jul 2016

Renal transplant recipients have a high incidence of hospitalization due to pyelonephritis, according to a Danish population-based cohort study.

Conference Reports
09 Mar 2017
Pearl Toh finds out from Professor Anna Lok, director of clinical hepatology at the University of Michigan in Ann Arbor, Michigan, US, on integrating guidelines, research data, and clinical setting in decision making for management of hepatitis B during the recent Asian Pacific Association for the Study of the Liver Annual Meeting held in Shanghai, China.

Pearl Toh, 08 Mar 2017
Add-on of pegylated interferon (pegIFN) to nucleos(t)ide analogues (NA) therapy may be a better strategy than a switch from NA to pegIFN in patients with chronic hepatitis B (CHB) who are on long-term NA therapy, according to data from an interim analysis of the SWAP* study presented at the recent Asian Pacific Association for the Study of the Liver Annual Meeting (APASL 2017) held in Shanghai, China.
Pearl Toh, 24 Feb 2017
The goal of treatment for portal hypertension varies depending on the different stages and substages of cirrhosis, and hence, pharmacological therapies for managing portal hypertension should be considered in the context of other complications of cirrhosis, according to a presentation at the recent APASL 2017 held in Shanghai, China recently.
24 Feb 2017
Slideshow: Highlights from the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL), Shanghai, China, February 15 - 19.
Roshini Claire Anthony, 23 Feb 2017

The use of statins is associated with a lower risk of pyogenic liver abscess, according to a Taiwan population-based case-control study. 

Roshini Claire Anthony, 22 Feb 2017

Individuals with hepatitis C virus (HCV) infection who achieve a sustained virological response (SVR) have improved liver stiffness and a lower risk of hepatocellular carcinoma (HCC), according to a presentation at the Asian Pacific Association for the Study of the Liver annual meeting (APASL 2017) in Shanghai, China.

Jairia Dela Cruz, 22 Feb 2017
An 8- to 16-week treatment regimen of elbasvir/grazoprevir plus sofosbuvir with or without ribavirin appears to be highly effective and well tolerated in both treatment-naïve and treatment-experienced cirrhotic patients with hepatitis C virus (HCV) genotype 3 (GT3) infection, according to the results of the C-ISLE study presented at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) held in Shanghai, China.